Letermovir for cytomegalovirus prophylaxis in lung transplant recipients: A promising shift toward reduced myelotoxicity
- PMID: 38742608
- DOI: 10.1111/tid.14277
Letermovir for cytomegalovirus prophylaxis in lung transplant recipients: A promising shift toward reduced myelotoxicity
References
REFERENCES
-
- Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger‐Isakov L, Humar A. The Third International Consensus Guidelines on the management of cytomegalovirus in solid‐organ transplantation. Transplantation. 2018;102:900‐931.
-
- Limaye AP, Haber B. Letermovir vs valganciclovir for cytomegalovirus prophylaxis after kidney transplant‐reply. JAMA. 2023;330:1803‐1804.
-
- Martinez S, Sindu D, Nailor MD. et al. Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients. Transpl Infect Dis. 2024;TID‐24‐OrA‐018.
-
- Newton CA, Kozlitina J, Lines JR, Kaza V, Torres F, Garcia CK. Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post‐lung transplantation survival. J Heart Lung Transplant. 2017;36:845‐853.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical